Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $24.3152W HIGH $115.52
Volume
1.21 M
Value Traded
89.74 M
Short % Float
12.97%
-2.69%Week
-10.41%1 Month
-2.9%3 Month
+33.77%6 Month
-87.51%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.44 B
EPS (TTM)
-2.01
P/E Ratio
-
Ent. Value
4.31 B
Total Shares
66.21 M
Float Shares
58.79 M
Insiders
11.21%
Institutions
103.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ORKA Catalyst Timeline
Dated clinical, regulatory and corporate events for Oruka Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oruka Therapeutics, Inc.
385Total events
10Upcoming
70Tier-1 (high impact)
2009 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutORKA-001Clinical Data
Positive Week 28 results from EVERLAST-A Phase 2a trial of ORKA-001
moderate-to-severe plaque psoriasissource ↗
▲Safety Data UpdateORKA-001Clinical Data
ORKA-001 maintained favorable safety profile through Week 28
moderate-to-severe plaque psoriasissource ↗
▲Additional DataORKA-001Clinical Data
Placebo crossover patients achieved PASI 100/PASI 90 rates similar to active arm at Week 28
moderate-to-severe plaque psoriasissource ↗
▲Trial InitiationORKA-002Trial
ORCA-SPLASH Phase 2 trial initiated
moderate-to-severe hidradenitis suppurativasource ↗
◆Topline ReadoutORKA-001Clinical Data
EVERLAST-A Week 28 data expected at end of 3Q 2026
moderate-to-severe plaque psoriasissource ↗
▲Partnership / LicenseORKA-001Corporate
Amended IL-23 license agreement with Paragon Therapeutics to include all therapeutic areas
▼Equity OfferingCorporate
Pricing of upsized $700 million underwritten public offering of 9,660,000 shares at $72.50 per share
▼Equity OfferingCorporate
Proposed $500 million underwritten public offering of common stock and pre-funded warrants
◆Topline ReadoutORKA-001Clinical Data
Week 16 data for ORKA-001 from EVERLAST-A trial
moderate-to-severe plaque psoriasissource ↗
●Oral PresentationORKA-001Presentation
Webcast of EVERLAST-A results
moderate-to-severe plaque psoriasissource ↗
◆Topline ReadoutORKA-001Clinical Data
Efficacy and response duration data from EVERLAST-A expected
moderate-to-severe psoriasissource ↗
▲Full ResultsORKA-001Clinical Data
EVERLAST-A Week 16 data: 63.5% PASI 100, 83% PASI 90, 84% IGA 0/1
moderate-to-severe plaque psoriasissource ↗
◆Trial InitiationORKA-002Trial
ORCA-SPLASH Phase 2 trial initiation
moderate-to-severe hidradenitis suppurativasource ↗
▲Enrollment CompleteORKA-001Trial
EVERLAST-B completed enrollment of 187 subjects in Q2 2026
moderate-to-severe plaque psoriasissource ↗
▲Oral PresentationORKA-001Presentation
Positive EVERLAST-A Week 16 data presented in April 2026
moderate-to-severe plaque psoriasissource ↗
●Quarterly UpdateCorporate
Preliminary cash, cash equivalents, and investments estimate of ~$496M as of March 31, 2026
▲Trial InitiationORKA-002Trial
ORCA-SURGE Phase 2 trial initiated
moderate-to-severe plaque psoriasissource ↗
◆Oral PresentationPresentation
Oruka Therapeutics presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Interim AnalysisORKA-002Trial
Positive interim Phase 1 data for ORKA-002 demonstrating half-life of 75-80 days
psoriasis, hidradenitis suppurativasource ↗
●Trial InitiationORKA-001Trial
Initiation of EVERLAST-B dose-ranging Phase 2b trial
moderate-to-severe plaque psoriasissource ↗
▲Trial InitiationORKA-002Trial
Initiate Phase 2 study of ORKA-002 in moderate-to-severe psoriasis
moderate-to-severe psoriasissource ↗
▲Interim AnalysisORKA-002Trial
Positive interim Phase 1 data for ORKA-002 (half-life ~75-80 days)
moderate-to-severe plaque psoriasissource ↗
◆Topline ReadoutORKA-002Clinical Data
Interim PK data from ORKA-002 Phase 1 trial expected in 1H 2026
psoriasissource ↗
◆Topline ReadoutORKA-002Clinical Data
Interim PK and safety data from Phase 1 healthy volunteer study
psoriasissource ↗
◆Interim AnalysisORKA-002Trial
Interim Phase 1 data including initial PK data expected
psoriasis (healthy volunteers)source ↗
●Oral PresentationORKA-001Presentation
Oral presentation on EVERLAST-A trial design at EADV
plaque psoriasissource ↗
◆Oral PresentationORKA-001Presentation
Interim Phase 1 data and EVERLAST-A study design details to be presented at EADV Congress
moderate-to-severe psoriasissource ↗
▲First Patient DosedORKA-001Trial
First patients dosed in EVERLAST-A Phase 2a trial of ORKA-001
moderate-to-severe plaque psoriasissource ↗
Past FDA Catalysts and PDUFA Decisions
How ORKA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | ORKA-001 | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C58 / 100
Pipeline Score
$2.5B
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 9%
Small Cap(rank 60 of 660)
Percentile Rank
Oruka Therapeutics, Inc. carries a moderate pipeline score (58/100), with $3.9B risk-adjusted pipeline value, led by ORKA-001 in Plaque Psoriasis (Phase 2), across $73B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORKA-002 Small moleculeNCT07474792 | Plaque Psoriasis | Phase 2 | RECRUITING | 160 | Apr 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every ORKA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ORKA-001 | moderate-to-severe plaque psoriasis | Phase 2a | 2026-09-23 | PASI 100: 71.4%; PASI 90: 87.3%; IGA 0 1: 84.1%; PASI 100 placebo crossover: 40.0%Read More | Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Klein Lawrence OttoDirector, Officer (Chief Executive Officer) | Option | 25,000 948,128 held | $7.80 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ORKA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| VR Adviser, LLC | 12 % (57.9 %) | 394.81 M | 4.15 M |
ORKA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ORKA ranks across every disease it competes in
Competitive Position is a premium feature
See how ORKA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialORKA News
ORKAOruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Oruka Therapeutics announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis. The data revealed a significant increase in PASI 100 and PASI 90 response rates, with a favorable safety profile maintained. The company anticipates sharing full 52-week data in December 2026.
Read more →ORKAOruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
Oruka Therapeutics will attend the 2026 Morgan Stanley Global Healthcare Conference in New York from September 14-16. The company is dedicated to developing novel biologics for chronic skin diseases, aiming for high rates of disease clearance with infrequent dosing. This participation highlights their commitment to advancing treatment options in the healthcare sector.
Read more →ORKAOruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
Oruka Therapeutics has appointed Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Edwards brings over 25 years of experience in commercial leadership within immunology and dermatology. His previous roles include significant contributions at Arcutis Biotherapeutics and Incyte Corporation. Oruka aims to advance its biologics for chronic skin diseases under his leadership.
Read more →ORKA▲ +6.4%on this news
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Oruka Therapeutics reported its second quarter 2026 financial results, highlighting significant advancements in its clinical pipeline. The company is on track to report key data from its EVERLAST-A and EVERLAST-B trials, with a Phase 3 program for ORKA-001 anticipated to begin in the first half of 2027. Additionally, ORKA-002's Phase 2 trial has been initiated, and the company maintains a strong cash position to support its ongoing projects.
Read more →ORKAOruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Oruka Therapeutics will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3rd. The company focuses on developing novel biologics for chronic skin diseases, including plaque psoriasis. Their goal is to provide effective treatments with infrequent dosing schedules, enhancing patient quality of life.
Read more →ORKAOruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Oruka Therapeutics has reported its first-quarter 2026 financial results alongside significant updates on its drug pipeline. Data from the EVERLAST-A trial showed a PASI 100 rate of 63.5% for its lead candidate, ORKA-001, which is well-tolerated. The company also initiated a Phase 2 trial for ORKA-002 and detailed a solid financial position, projecting sufficient funds through its upcoming BLA filing for ORKA-001. Future data releases are anticipated in 2026 and 2027, which may further influence their market standing.
Read more →ORKARecent Developments Certain Financial and Operating Data for First Quarter 2026 While we have not finalized our full financial results for the quarter ended
The article discusses the preliminary financial data for ORKA for the first quarter of 2026, highlighting an estimated cash, cash equivalents, and investments totaling approximately $496 million as of March 31, 2026. It underscores that these figures are not yet finalized and are subject to revision based on the closing of accounting records. The report emphasizes that the data has not been audited or reviewed by PricewaterhouseCoopers LLP, indicating a need for caution in relying on this preliminary estimate.
Read more →ORKAOruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
Oruka Therapeutics has announced the pricing of its upsized public offering, raising approximately $700.4 million by selling 9,660,000 shares at $72.50 each. The offering is set to close around April 30, 2026, pending customary conditions. The funds will aid in advancing Oruka's monoclonal antibody therapeutics for chronic skin diseases.
Read more →ORKA▲ +10.7%on this newsshared move
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics announced positive interim results from the EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis. The trial showed that 63.5% of participants achieved complete skin clearance at Week 16. The safety profile was favorable, with no serious adverse events reported. Future data updates are expected in 2026.
Read more →ORKA▲ +10.7%on this newsshared move
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
Oruka Therapeutics has announced a proposed underwritten public offering of $500 million in common stock, with an additional option for underwriters to purchase up to $75 million more. The offering is intended to support the company's development of novel monoclonal antibody therapeutics for psoriasis and other inflammatory conditions. However, the completion of the offering is contingent on market conditions.
Read more →ORKA▲ +10.7%on this newsshared move
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
Oruka Therapeutics will report Week 16 data for ORKA-001 from the EVERLAST-A Phase 2a trial on April 27, 2026. The trial focuses on moderate-to-severe plaque psoriasis. Following the data release, a conference call will be held to discuss the results. The company aims to set a new standard in treating chronic skin diseases.
Read more →ORKA▲ +25%on this news
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of $479.6 million. The company announced the completion of enrollment for its EVERLAST-A trial and the initiation of the ORKA-002 Phase 2 trial for psoriasis. However, it also noted an increase in net loss and R&D expenses.
Read more →ORKAOruka Therapeutics to Participate in Multiple Upcoming Conferences
Oruka Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming conferences, including the Guggenheim Emerging Outlook: Biotech Summit and the TD Cowen Annual Health Care Conference. The company is focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis, aiming to provide patients with effective treatment options. Presentations will be available via webcast on their investor events website.
Read more →ORKA▲ +10.2%on this news
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
Oruka Therapeutics has announced positive interim Phase 1 data for ORKA-002, indicating a long half-life that could allow for less frequent dosing in treating psoriasis and hidradenitis suppurativa. The company plans to initiate Phase 2 trials for ORKA-002 in 2026 and reports ongoing advancement in the EVERLAST-B Phase 2b trial for ORKA-001, with data expected in 2027. CEO Lawrence Klein expressed confidence in the emerging product profiles of both assets and their potential role in treating chronic skin diseases. Safety outcomes from ORKA-002 trials have been favorable, helping to bolster expectations for future development.
Read more →ORKAOruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Oruka Therapeutics, a clinical stage biotechnology company focused on chronic skin disease treatments, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. The company aims to improve treatment for plaque psoriasis, highlighting its commitment to developing novel biologics. A webcast of the presentation will be available online for investors and stakeholders.
Read more →ORKAOruka Therapeutics Announces New Board Member and Board Transition
Oruka Therapeutics has announced the appointment of Chris Martin to its Board of Directors, highlighting his considerable commercial experience. This transition coincides with the resignation of Cameron Turtle, who has contributed significantly to the company's early strategy. The CEO expressed optimism about Martin's ability to advance the company's late-stage development efforts, particularly regarding products ORKA-001 and ORKA-002. Oruka is focused on developing innovative biologics for chronic skin diseases, including plaque psoriasis.
Read more →ORKA▼ -6.8%on this news
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics reported strong financial results for Q3 2025, highlighting promising data from its ORKA-001 Phase 1 trial. The company has over $500 million in cash, ensuring a runway beyond key upcoming clinical readouts. ORKA-001 is showing potential for effective treatment with less frequent dosing, while the ORKA-002 Phase 1 trial is ongoing.
Read more →ORKAOruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics, a clinical-stage biotechnology firm, has announced its participation in several investor conferences in November 2025. These include the Guggenheim 2nd Annual Healthcare Innovation Conference, the Stifel 2025 Healthcare Conference, and the Jefferies Global Healthcare Conference. The company is focused on developing biologics for chronic skin diseases such as plaque psoriasis.
Read more →ORKA▲ +8.8%on this news
Oruka Therapeutics Announces $180 Million Private Placement
Oruka Therapeutics has announced a $180 million private placement to support its operations and research. The financing, led by Viking Global Investors, involves the sale of over 10 million shares at $15 each. The company plans to use the proceeds for R&D and general corporate expenses, ensuring operational funding for at least one year post Phase 2 trial data readouts.
Read more →ORKA▲ +8.8%on this newsshared move
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Oruka Therapeutics has announced positive interim results from its Phase 1 trial of ORKA-001, a long-acting IL-23p19 antibody for plaque psoriasis. The drug's promising 100-day half-life may allow for once-per-year dosing, with ongoing trials aiming to demonstrate higher efficacy and extended off-treatment remissions. Initial data from the subsequent Phase 2a trial is expected in the second half of 2026.
Read more →About Oruka Therapeutics, Inc.
Headquarters855 OAK GROVE AVE., MENLO PARK, CA, 94025
BIOPHARMAWATCH ELITE PLUS
Trade the next ORKA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime